Fingerprint Drug Test Gains Ground: Intelligent Bio Solutions Expands U.S. Presence

Imagine a drug test that doesn’t require peeing in a cup. Intelligent Bio Solutions (NASDAQ: INBS) is working to make that a reality. In a recent press release, the biotech firm shared major milestones in rolling out its non-invasive fingerprint drug screening system across the U.S. forensic market—with eyes on even broader use.

From Fingerprints to Fast Results

In partnership with Texas-based drug screening provider SMARTOX, INBS has deployed more than 50 of its Intelligent Fingerprinting Drug Screening Readers, logging over 7,000 drug tests—including 1,500+ already in 2024. The system analyzes sweat from a fingerprint and delivers results in under ten minutes—no urine, no saliva, no lab delays.

Forensic Footprint, FDA Ambitions

While currently restricted to forensic use only, the company is actively pursuing FDA clearance for its codeine test—part of a broader plan to expand into workplace drug testing markets later this year. INBS hopes its fingerprint-based method will streamline testing logistics, reduce costs, and eliminate the need for gender-specific collection staff.

SMARTOX Sees Results

SMARTOX, which serves corrections, rehab centers, and drug courts, praised the tech’s ease of use and impact on efficiency. “Our clients consistently report that the system improves efficiency, enhances user dignity, and simplifies operations,” said Duffy Nabors, VP of Sales and Marketing at SMARTOX.

A Possible Shift in Drug Testing Norms?

If FDA approval is granted, INBS’ technology could represent a meaningful shift in how drug testing is conducted—not just in courts, but in corporate America. With faster turnaround times, lower staffing needs, and a more discreet collection process, fingerprint drug tests might soon become the new standard in a compliance-heavy world.

For the full press release, visit the original source (via Stock Titan): Intelligent Bio Solutions Expands U.S. Forensic Market Presence.